Presentation is loading. Please wait.

Presentation is loading. Please wait.

Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen- induced asthmatic reactions  Emmerentia van Schalkwyk, MBChB, K. Strydom,

Similar presentations


Presentation on theme: "Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen- induced asthmatic reactions  Emmerentia van Schalkwyk, MBChB, K. Strydom,"— Presentation transcript:

1 Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen- induced asthmatic reactions  Emmerentia van Schalkwyk, MBChB, K. Strydom, MBChB, Zelda Williams, RN, Louis Venter, MSc, Stefan Leichtl, PhD, Christine Schmid-Wirlitsch, PhD, Dirk Bredenbröker, MD, Philip G. Bardin, FRACP, PhD  Journal of Allergy and Clinical Immunology  Volume 116, Issue 2, Pages (August 2005) DOI: /j.jaci Copyright © 2005 American Academy of Allergy, Asthma and Immunology Terms and Conditions

2 Fig 1 Study design. In this randomized, double-blind, 3-period crossover study, each treatment period lasted 7 to 10 days and was preceded by a 2- to 5-week washout period. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2005 American Academy of Allergy, Asthma and Immunology Terms and Conditions

3 Fig 2 Mean percentage decrease of FEV1 from postsaline value after allergen challenge. Roflumilast, 250 and 500 μg, significantly attenuated the EAR (0-2 hours) and LAR (2-12 hours) compared with placebo. Data are presented for the intent-to-treat population. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2005 American Academy of Allergy, Asthma and Immunology Terms and Conditions


Download ppt "Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen- induced asthmatic reactions  Emmerentia van Schalkwyk, MBChB, K. Strydom,"

Similar presentations


Ads by Google